Fig. 1: Signature of hepatic ferroptosis in subset of MASLD patients. | Cell Death & Differentiation

Fig. 1: Signature of hepatic ferroptosis in subset of MASLD patients.

From: Ferroptosis is a targetable detrimental factor in metabolic dysfunction-associated steatotic liver disease

Fig. 1

Ferroptosis markers in liver biopsies from controls (n = 5), MASLD patients with isolated steatosis (MASL, n = 8), metabolic dysfunction-associated steatohepatitis without (MASH F0-1, n = 7) or with significant fibrosis (MASH F2-3, n = 7). A Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) stain (red) with DAPI (blue). B Immunohistochemistry (IHC) for 4-hydroxynonenal (4HNE). Red arrows indicate aggregates of ferroptosis breakdown products. C, D IHC glutathione peroxidase 4 (GPX4) and acyl-CoA synthetase long-chain family member 4 (ACSL4). Contours of nuclei, cytoplasm and lipid vacuoles annotated. Magnification 400×, scale bar 50 µm. E TUNEL, 4HNE, GPX4 and ACSL4 in clusters 1, 2 and 3 as determined by k-prototypes partitioning clustering. Mean ± standard deviation. *p < 0.05; **p < 0.01; ***p < 0.001; Kruskal–Wallis with Dunn’s test.

Back to article page